Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C30H26O13 |
| Molecular Weight | 594.5196 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 5 / 5 |
| E/Z Centers | 1 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
O[C@@H]1[C@@H](COC(=O)\C=C\C2=CC=C(O)C=C2)O[C@@H](OC3=C(OC4=C(C3=O)C(O)=CC(O)=C4)C5=CC=C(O)C=C5)[C@H](O)[C@H]1O
InChI
InChIKey=DVGGLGXQSFURLP-VWMSDXGPSA-N
InChI=1S/C30H26O13/c31-16-6-1-14(2-7-16)3-10-22(35)40-13-21-24(36)26(38)27(39)30(42-21)43-29-25(37)23-19(34)11-18(33)12-20(23)41-28(29)15-4-8-17(32)9-5-15/h1-12,21,24,26-27,30-34,36,38-39H,13H2/b10-3+/t21-,24-,26+,27-,30+/m1/s1
| Molecular Formula | C30H26O13 |
| Molecular Weight | 594.5196 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 5 / 5 |
| E/Z Centers | 1 |
| Optical Activity | UNSPECIFIED |
DescriptionSources: http://www.iscd.it/files/Tiliroside-and-Dihydroxy-Methylchromone---from-Nature-to-Cosmetic-Applications.pdfCurator's Comment: The description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/26498393 | https://www.ncbi.nlm.nih.gov/pubmed/28539736 | https://www.ncbi.nlm.nih.gov/pubmed/28704976 | https://www.ncbi.nlm.nih.gov/pubmed/27347085
Sources: http://www.iscd.it/files/Tiliroside-and-Dihydroxy-Methylchromone---from-Nature-to-Cosmetic-Applications.pdf
Curator's Comment: The description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/26498393 | https://www.ncbi.nlm.nih.gov/pubmed/28539736 | https://www.ncbi.nlm.nih.gov/pubmed/28704976 | https://www.ncbi.nlm.nih.gov/pubmed/27347085
Tiliroside is a glycosidic flavonoid, which possesses anti-inflammatory, antioxidant, anticarcinogenic and hepatoprotective activities. In vitro Tiliroside shows antidiabetic properties by enhancing glucose consumption by insulin resistant HepG2 cells, antihypertensive and vasorelaxant effects in resis¬tance arteries, antihyperglycemic, antihyperlipidemic and antioxidant activities; as well as an inhibitory effect on important human liver cytochrome p450 enzymes. In vivo, Tiliroside significantly inhibited the mouse paw edema induced by phospholipase A and the mouse ear inflammation induced by 12 O tetradecanoylphorbol- 13-acetate. Tiliroside can be found in the hairy shields and young leaves of plants growing in tropical regions of the world. Tiliroside protects these plants from UV-induced and environmental stress and can be used as anti-aging and anti-inflammatory agent for cosmetic applications.
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL2326 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26498393 |
4.6 nM [Ki] | ||
Target ID: CHEMBL3729 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26498393 |
5468.7 nM [Ki] | ||
Target ID: CHEMBL3242 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26498393 |
134.3 nM [Ki] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Unknown Approved UseUnknown |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Flavonoids possess neuroprotective effects on cultured pheochromocytoma PC12 cells: a comparison of different flavonoids in activating estrogenic effect and in preventing beta-amyloid-induced cell death. | 2007-03-21 |
|
| Flavonol 3-O-glycoside hydroxycinnamoyltransferases from Scots pine (Pinus sylvestris L.). | 2005-03 |
|
| Screening of the inhibitory effect of vegetable constituents on the aryl hydrocarbon receptor-mediated activity induced by 2,3,7,8-tetrachlorodibenzo-p-dioxin. | 2003-12 |
|
| The anti-HIV activity and mechanisms of action of pure compounds isolated from Rosa damascena. | 1996-12-04 |
|
| Evaluation of natural products as inhibitors of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase. | 1991-01-01 |
Sample Use Guides
The formulation (Tiliroside 0.1 % w/v) were applied twice daily (morning and evening) in normal conditions of use during 28 days.
Route of Administration:
Topical
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/27347085
To determine the effect of tiliroside on cell viability, RAW 264.7 cells were cultured in 96 well plates at a density of 2x10^5 cells/well. Following a 24 h incubation period, the cells were then treated with seri¬ally diluted tiliroside at concentrations of 1.5625 100 μM. The mitochondrial dependent reduction of MTT to formazan was used to measure cell respiration as an indicator of cell viability
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 19:57:00 GMT 2025
by
admin
on
Mon Mar 31 19:57:00 GMT 2025
|
| Record UNII |
15M04TXR9M
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
15M04TXR9M
Created by
admin on Mon Mar 31 19:57:00 GMT 2025 , Edited by admin on Mon Mar 31 19:57:00 GMT 2025
|
PRIMARY | |||
|
DTXSID601021936
Created by
admin on Mon Mar 31 19:57:00 GMT 2025 , Edited by admin on Mon Mar 31 19:57:00 GMT 2025
|
PRIMARY | |||
|
1423792
Created by
admin on Mon Mar 31 19:57:00 GMT 2025 , Edited by admin on Mon Mar 31 19:57:00 GMT 2025
|
PRIMARY | RxNorm | ||
|
5320686
Created by
admin on Mon Mar 31 19:57:00 GMT 2025 , Edited by admin on Mon Mar 31 19:57:00 GMT 2025
|
PRIMARY | |||
|
20316-62-5
Created by
admin on Mon Mar 31 19:57:00 GMT 2025 , Edited by admin on Mon Mar 31 19:57:00 GMT 2025
|
PRIMARY | |||
|
15M04TXR9M
Created by
admin on Mon Mar 31 19:57:00 GMT 2025 , Edited by admin on Mon Mar 31 19:57:00 GMT 2025
|
PRIMARY | |||
|
300000008663
Created by
admin on Mon Mar 31 19:57:00 GMT 2025 , Edited by admin on Mon Mar 31 19:57:00 GMT 2025
|
PRIMARY | |||
|
C052083
Created by
admin on Mon Mar 31 19:57:00 GMT 2025 , Edited by admin on Mon Mar 31 19:57:00 GMT 2025
|
PRIMARY |